Background {#Sec1}
==========

Lewy body dementia (LBD) includes dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) and is the second most common form of neurodegenerative dementia after Alzheimer's disease (AD) \[[@CR1]\]. LBD is characterised by Parkinsonism, fluctuating cognition, rapid eye movement sleep behaviour disorder, and visual hallucinations \[[@CR2]\].

Both LBD and AD patients show marked cholinergic deficits which are more severe in LBD compared to AD and occur earlier in the course of the disease \[[@CR3], [@CR4]\]. In LBD, the cortical cholinergic deficit is mainly caused by degeneration of cholinergic nuclei within the basal forebrain \[[@CR5]\]. The substantia innominata forms part of the basal forebrain and contains the nucleus basalis of Meynert (NBM) whose cholinergic neurons have widespread connections to the entire cortex providing the main source of cortical cholinergic innervation \[[@CR6]\]. Several studies have identified structural abnormalities within the substantia innominata in LBD which are more pronounced than in AD \[[@CR7], [@CR8]\].

Cholinergic deficits are believed to be one of the major causes of cognitive dysfunction in dementia. In Parkinson's disease, loss of cholinergic neurons in the NBM and cortical cholinergic dysfunction are related to the development of dementia \[[@CR9], [@CR10]\] and NBM degeneration is predictive of future cognitive decline \[[@CR11]\]. In AD patients, NBM volume is correlated with overall cognitive performance \[[@CR12]\].

In particular, cognitive fluctuations, which are a common symptom of both DLB and PDD, have been linked to imbalances within the cholinergic system \[[@CR13]\]. Structural abnormalities in the substantia innominata have been shown to be related to the severity of cognitive fluctuations in DLB \[[@CR7]\], and cholinesterase inhibitors can ameliorate this clinical symptom \[[@CR14]\].

Previous studies have found an association between cholinergic innervation from subcortical structures and cortical neural signals as measured by EEG. In resting, eyes-closed conditions, a prominent rhythm in the alpha frequency range can be observed in the EEG which results from the synchronous firing of many cortical neurons summing to form large-amplitude signals \[[@CR15]\]. In the healthy brain, opening of the eyes leads to a marked attenuation of alpha power due to desynchronization of neuronal activity \[[@CR15], [@CR16]\]. The magnitude of this reduction in alpha power from eyes closed to eyes open---termed alpha reactivity---has been suggested as a marker of cholinergic system integrity \[[@CR17], [@CR18]\].

Studies in AD found a decrease in alpha reactivity compared to healthy controls \[[@CR19], [@CR20]\]. This reduced alpha reactivity in AD has been shown to be related to the severity of cognitive impairment and was also observed in individuals with amnestic mild cognitive impairment (MCI) who are at an increased risk of developing AD, suggesting that changes in alpha reactivity might occur early in the course of the disease \[[@CR20]\].

Franciotti et al. \[[@CR21]\] investigated differences in alpha reactivity between AD and DLB patients using magnetencephalography (MEG). While they observed a decrease in alpha reactivity in the dementia groups compared to controls, they did not find differences between AD and DLB which might be due to the small sample size including only seven DLB patients \[[@CR21]\]. Similarly, Bosboom et al. \[[@CR22]\] found a reduction in alpha reactivity in PDD patients compared to controls using MEG.

However, no previous study has investigated differences in alpha reactivity between AD and LBD in a larger cohort, and how changes in alpha reactivity relate to cholinergic system integrity in these patients.

The first aim of the present study was therefore to assess alpha reactivity in a cohort of LBD patients compared to AD patients with similar levels of cognitive impairment and to healthy age-matched controls. We hypothesised that alpha reactivity would be reduced in the dementia groups with a more pronounced decrease in LBD compared to AD given the more severe cholinergic deficit in the former group \[[@CR3]\]. The second aim was to investigate the association between changes in alpha reactivity and volumetric changes within the cholinergic system in LBD and AD. Here, we hypothesised that a reduction in alpha reactivity would be related to reductions in NBM volume in the dementia groups. Based on evidence from previous studies suggesting a link between cognitive fluctuations and disturbances within the cholinergic system \[[@CR7]\], we also hypothesised that a reduction in alpha reactivity would be related to more severe cognitive fluctuations in LBD.

Methods {#Sec2}
=======

Participants {#Sec3}
------------

This study involved 102 participants over 60 years of age. Forty-one were diagnosed with probable LBD (24 DLB and 17 PDD), 21 were diagnosed with probable AD, and 40 were healthy controls of similar age with no history of psychiatric or neurological illness. Patients were recruited from the local community-dwelling population who had been referred to old-age psychiatry and neurology services. The study was approved by the local ethics committee, and written informed consent was obtained from all participants. Dementia diagnoses were performed independently by two experienced clinicians in alignment with consensus criteria for probable DLB \[[@CR2]\], PDD \[[@CR23]\], and AD \[[@CR24]\]. Patients who were taking dopaminergic medication were assessed in the "ON" motor state.

All participants underwent detailed neurological and neuropsychiatric testing including the Mini-Mental State Examination (MMSE) as a measure of global cognition, the Unified Parkinson's Disease Rating Scale part III for the assessment of Parkinsonian motor problems, and the Neuropsychiatric Inventory (NPI) hallucinations subscale which was specifically focussed on the occurrence of visual hallucinations. For the assessment of cognitive fluctuations, we used the Mayo Fluctuation Scale \[[@CR25]\].

EEG acquisition and pre-processing {#Sec4}
----------------------------------

Resting state EEG recordings were acquired from all participants using Waveguard caps (ANT Neuro, The Netherlands) comprising 128 sintered Ag/AgCl electrodes that were placed according to the 10--5 system. Participants were seated during the recording and instructed to remain awake. Electrode impedance was kept below 5 kΩ, and continuous EEG data were recorded at a sampling frequency of 1024 Hz. One hundred fifty seconds of eyes-closed and 150 s of eyes-open data were recorded from each participant. Participants were supervised by the EEG technician during the recording to monitor adherence to the protocol (i.e. eyes open vs eyes closed). The ground electrode was attached to the right clavicle, and all EEG channels were referenced to Fz during recording.

Pre-processing of eyes-closed and eyes-open EEG data was performed blinded to group membership, and the methods applied were the same as described in \[[@CR26]\]. Briefly, data were filtered between 0.3 and 54 Hz using a second order Butterworth filter, noisy EEG segments and noisy EEG channels were deleted, and independent component analysis was used for artefact removal. The deleted channels were then replaced using spherical spline interpolation, and data were recomputed against the average reference and split into non-overlapping epochs of 2 s. For each participant, the first 45 2-s long artefact-free epochs from the eyes-closed data and the first 45 2-s long artefact-free epochs from the eyes-open data were selected for further analysis.

Alpha reactivity analysis {#Sec5}
-------------------------

EEG data from three occipital electrodes (O1, O2, and Oz) were selected for the alpha reactivity analysis (Fig. [2](#Fig2){ref-type="fig"}a) \[[@CR17]\]. For each electrode separately, the power spectral density (PSD) was estimated using Bartlett's method with a frequency resolution of 0.25 Hz and a Hamming window. The resulting PSD for the three electrodes was averaged across the 45 epochs and across the three electrodes for each condition separately (eyes open and eyes closed). Alpha reactivity was then calculated according to the following formula \[[@CR17]\]: $$\documentclass[12pt]{minimal}
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                \begin{document}$$ \mathrm{alpha}\ \mathrm{reactivity}=\frac{\mathrm{alpha}\ \mathrm{power}\ \mathrm{eyes}\ \mathrm{closed}-\mathrm{alpha}\ \mathrm{power}\ \mathrm{eyes}\ \mathrm{open}}{\mathrm{alpha}\ \mathrm{power}\ \mathrm{eyes}\ \mathrm{closed}} $$\end{document}$$where alpha power was computed as the relative power within a frequency bin around the individual alpha peak frequency ± 2 Hz. Individual alpha peak frequencies were calculated by finding the peak in the PSD in the extended alpha frequency band from 4 to 14 Hz \[[@CR20]\] using the eyes-closed data. Individual alpha peak frequencies were used instead of the standard alpha frequency band to account for a shift of the alpha peak to slower frequencies in AD and LBD \[[@CR26], [@CR27]\].

MRI acquisition and pre-processing {#Sec6}
----------------------------------

There were 40 healthy controls, 19 AD, 20 DLB, and 16 PDD participants from the alpha reactivity analysis with structural MRI data. MR images were acquired on a 3-T Philips Intera Achieva scanner with a magnetization prepared rapid gradient echo (MPRAGE) sequence, sagittal acquisition, echo time 4.6 ms, repetition time 8.3 ms, inversion time 1250 ms, flip angle = 8°, SENSE factor = 2, and in-plane field of view 240 × 240 mm^2^ with slice thickness 1.0 mm, yielding a voxel size of 1.0 × 1.0 × 1.0 mm^3^.

Pre-processing of MR images was performed in SPM12 (<http://www.fil.ion.ucl.ac.uk/spm/>). First, images were segmented into grey matter, white matter, and cerebrospinal fluid. The segmented grey matter images were then coregistered and normalised to MNI space using SPM's DARTEL algorithm \[[@CR28]\] and modulated. As a final step, images were smoothed with a 4-mm full width at half maximum Gaussian kernel.

Analysis of nucleus basalis of Meynert volumes {#Sec7}
----------------------------------------------

The NBM was identified using a probabilistic anatomical map from the SPM Anatomy Toolbox \[[@CR29]\] which was created using microscopic delineations of ten post-mortem human brains \[[@CR30]\]. The NBM forms part of the basal forebrain which consists of cholinergic cells that can be histologically defined as Ch1--Ch6 where Ch4 corresponds to the NBM \[[@CR31]\]. A region of interest mask for the NBM was created using the SPM Anatomy Toolbox (see Fig. [1](#Fig1){ref-type="fig"}). NBM volume was averaged across the right and left hemispheres. For each participant, grey matter volume within the mask was calculated. Additionally, the total intracranial volume was calculated in SPM to normalise NBM volume. Fig. 1Nucleus basalis of Meynert mask. Region of interest mask for the NBM in MNI space, estimated from the SPM Anatomy Toolbox

Statistics {#Sec8}
----------

Individual alpha peak frequency, alpha reactivity, and alpha power (eyes open and eyes closed) were compared between the groups using univariate ANOVAs or Kruskal-Wallis ANOVAs depending on whether the data were normally distributed. Post hoc tests were Bonferroni-corrected for multiple comparisons. The same analysis was used to compare NBM volume (corrected for total intracranial volume) between groups. Correlations between alpha reactivity and NBM volume were computed using Spearman's correlations, across all groups and separately in each clinical group. Additionally, Spearman's correlations between alpha reactivity and NBM volumes and clinical scores were tested for the Mayo Fluctuation Scale (total score and cognitive subscore) and for the MMSE as a measure of overall cognition, in each dementia group separately. False discovery rate (FDR) correction was used to correct correlation *p* values for multiple comparisons.

To assess the influence of dopaminergic medication, the EEG measures were compared between those LBD patients taking dopaminergic medication (*N* = 28) and those not taking dopaminergic medication (*N* = 13) using two-sample *t* tests. Additionally, we assessed Spearman's correlations between levodopa equivalent daily dose (LEDD) \[[@CR32]\] and the EEG measures in those LBD patients who were on dopaminergic medication.

Results {#Sec9}
=======

Demographics {#Sec10}
------------

All three groups were similar in age (see Table [1](#Tab1){ref-type="table"}). Although not statistically significant, there was a tendency for group differences in terms of gender, i.e. LBD patients were predominantly male whereas gender was more balanced in the AD group. To make sure that results were not influenced by these gender differences between groups, all group comparisons were repeated including gender as a covariate. The AD and LBD groups did not differ significantly with respect to overall cognition (MMSE) and dementia duration. As expected, the LBD patients were more impaired than AD in terms of the core LBD symptoms of Parkinsonism, cognitive fluctuations, and visual hallucinations. The percentage of patients taking cholinesterase inhibitors was similar in both dementia groups whereas the majority of LBD patients were taking dopaminergic medication compared to none of the AD patients. Table 1Demographic and clinical variables, mean (standard deviation)HC (*N* = 40)AD (*N* = 21)LBD (*N* = 41)Group differencesMale to female25:1514:735:6*χ*^2^ = 5.8, *p* = 0.06^a^Age73.4 (6.6)74.7 (7.2)74.6 (6.5)*F*(2, 99) = 0.4, *p* = 0.66^b^AChEI--2035*χ*^2^ = 1.4, *p* = 0.25^c^PD meds--028*χ*^2^ = 26.2, *p* \< 0.001^c^Duration--4.1 (2.4)^f^3.2 (2.1)^g^*U* = 270, *p* = 0.07^d^MMSE28.8 (1.1)21.6 (3.7)23.1 (3.8)*t*~60~ = 1.5, *p* = 0.15^e^UPDRS III3.9 (4.2)1.7 (1.5)20.2 (8.6)*t*~60~ = 9.7, *p* \< 0.001^e^CAF total--0.3 (0.7)^h^5.2 (4.3)^j^*t*~56~ = 5.1, *p* \< 0.001^e^Mayo total--9.4 (4.4)^h^14.3 (5.5)^j^*t*~56~ = 3.5, *p* = 0.001^e^Mayo cogn--2.0 (1.9)^h^3.0 (1.8)^j^*t*~56~ = 2.0, *p* = 0.05^e^NPI total--7.4 (7.2)^h^14.5 (10.5)^g^*t*~58~ = 2.7, *p* = 0.009^e^NPI hall--0.05 (0.2)^h^2.0 (2.0)^g^*t*~58~ = 4.5, *p* \< 0.001^e^*AChEI* number of patients taking acetylcholinesterase inhibitors, *AD* Alzheimer's disease, *CAF total* Clinician Assessment of Fluctuation total score, *Duration* duration of cognitive symptoms in years, *HC* healthy controls, *LBD* Lewy body dementia, *Mayo total* Mayo Fluctuation Scale, *Mayo cognitive* Mayo Fluctuation cognitive subscale, *MMSE* Mini-Mental State Examination, *PD meds* number of patients taking dopaminergic medication for the management of Parkinson's disease symptoms, *UPDRS III* Unified Parkinson's Disease Rating Scale III (motor subsection), *NPI* Neuropsychiatric Inventory, *NPI hall* NPI hallucination subscore^a^Chi-square test HC, AD, LBD^b^One-way ANOVA HC, AD, LBD^c^Chi-square test AD, LBD^d^Mann-Whitney *U* test AD, LBD^e^Student's *t* test AD, LBD^f^*N* = 19^g^*N* = 40^h^*N* = 20^j^*N* = 38

When considering only the participants that were included in the combined EEG-MRI analysis, all groups were still matched for age and gender, and the dementia groups were matched for overall cognition (Supplementary Table S[1](#MOESM1){ref-type="media"}).

The DLB and PDD subgroups were comparable in age, gender, overall cognition, dementia duration, the percentage of patients taking cholinesterase inhibitors, cognitive fluctuations, and visual hallucinations (Supplementary Table S[2](#MOESM1){ref-type="media"}). More PDD patients were taking dopaminergic medication compared to DLB, the levodopa equivalent daily dose (LEDD) was higher in PDD compared to DLB, and they had worse Parkinsonism and total NPI symptom scores.

Alpha reactivity {#Sec11}
----------------

Individual alpha peak frequency was significantly lower in both dementia groups compared to controls with no significant difference between LBD and AD (Table [2](#Tab2){ref-type="table"}). Table 2Group comparison of EEG characteristics and NBM volumeHCADLBDGroup comparisonIndividual alpha peak8.8 \[8.4, 9.2\]7.4 \[6.3, 8.4\]6.4 \[6.1, 6.7\]*F*~2~ = 42.1, *p* \< 0.001^a^*p* (HC, AD) = 0.004*p* (HC, LBD) \< 0.001*p* (AD, LBD) = 0.092Alpha reactivity0.56 \[0.50, 0.63\]0.24 \[0.12, 0.34\]0.08 \[0.03, 0.14\]*F*~2~ = 59.9, *p* \< 0.001^b^*p* (HC, AD) \< 0.001*p* (HC, LBD) \< 0.001*p* (AD, LBD) = 0.014Eyes-closed alpha power49.1 \[41.9, 56.3\]34.4 \[27.5, 41.3\]39.7 \[35.8, 43.5\]*F*~2~ = 7.9, *p* = 0.019^a^*p* (HC, AD) = 0.018*p* (HC, LBD) = 0.25*p* (AD, LBD) = 0.56Eyes-open alpha power18.9 \[16.1, 21.7\]24.2 \[19.4, 29.0\]36.7 \[32.4, 41.1\]*F*~2~ = 35.5, *p* \< 0.001^a^*p* (HC, AD) = 0.25*p* (HC, LBD) \< 0.001*p* (AD, LBD) = 0.005NBM volume0.19 \[0.18, 0.20\]0.17 \[0.16, 0.17\]0.16 \[0.15, 0.17\]*F*~2~ = 13.3, *p* \< 0.001^b^*p* (HC, AD) = 0.003*p* (HC, LBD) \< 0.001*p* (AD, LBD) = 1.0Mean \[95% confidence interval\]. Alpha power and alpha reactivity estimated from electrodes O1, Oz, and O2 using individual alpha peak frequencies. NBM volume normalised to total intracranial volume. Group differences assessed by univariate ANOVA or Kruskal-Wallis ANOVA with post hoc tests corrected for multiple comparisons*AD* Alzheimer's disease, *HC* healthy controls, *LBD* Lewy body dementia, *NBM* nucleus basalis of Meynert^a^Kruskal-Wallis ANOVA^b^Univariate ANOVA

Alpha reactivity was reduced in both dementia groups compared to controls and was significantly more reduced in LBD compared to AD (Table [2](#Tab2){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}a). Eyes-closed alpha power was reduced in AD compared to controls, but there were no significant differences between LBD and controls or between AD and LBD. In contrast, eyes-open alpha power (taking into account individual alpha peak frequencies) was significantly increased in LBD compared to both controls and AD while there was no significant difference between AD and controls (Fig. [2](#Fig2){ref-type="fig"}b). Fig. 2Alpha reactivity analysis. **a** Occipital EEG signals of example control and DLB participants in eyes-closed (blue) and eyes-open (red) conditions. **b** Comparison of mean power spectra for eyes-closed and eyes-open conditions for the different clinical groups. Shaded areas indicate standard errors. AD, Alzheimer's disease; DLB, dementia with Lewy bodies; HC, healthy controls; PDD, Parkinson's disease dementia

There were no significant differences between the DLB and PDD subgroups in terms of individual alpha peak frequency, alpha reactivity, or eyes-closed and eyes-open alpha power (see Supplementary Table S[3](#MOESM1){ref-type="media"}).

There was a significant positive correlation between individual alpha peak frequency and alpha reactivity in the AD group (*ρ* = 0.77, *p* \< 0.001), but no significant correlations in DLB (*ρ* = 0.37, *p* = 0.08), PDD (*ρ* = 0.33, *p* = 0.19), or controls (*ρ* = 0.12, *p* = 0.46).

The results with respect to alpha reactivity did not change when considering the standard alpha frequency band from 8 to 12 Hz instead of individual alpha peak frequencies (see Section 3 of the [Supplementary Material](#MOESM1){ref-type="media"}).

Results from all group comparisons did not change when including gender as a covariate (see Supplementary Table S[5](#MOESM1){ref-type="media"}).

NBM volume {#Sec12}
----------

Normalised NBM volume was decreased in the AD and LBD groups compared to controls; however, there was no significant difference between the dementia groups (see Table [2](#Tab2){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}b). There was no difference in normalised NBM volume between the DLB and PDD subgroups (see Supplementary Table S[3](#MOESM1){ref-type="media"}). Fig. 3Group comparison. **a** Group comparison of alpha reactivity. **b** Group comparison of NBM volumes (normalised with respect to total intracranial volume). In each boxplot, the central line corresponds to the sample median; the upper and lower borders of the box represent the 25th and 75th percentile, respectively; and the length of the whiskers is 1.5 times the interquartile range. Corresponding results from statistical comparisons between the groups are presented in Table [2](#Tab2){ref-type="table"}. AD, Alzheimer's disease; DLB, dementia with Lewy bodies; HC, healthy controls; NBM, nucleus basalis of Meynert; PDD, Parkinson's disease dementia

Mean (standard deviation) of total intracranial volumes in litres were 1.44 (0.11) in the control group, 1.42 (0.13) in the AD group, and 1.54 (0.15) in the LBD group.

Association between alpha reactivity and NBM volume {#Sec13}
---------------------------------------------------

When considering the whole group (across AD, LBD, and controls), there was a significant positive correlation between alpha reactivity and NBM volume (*ρ* = 0.42, *p*~FDR~ = 0.0001, Fig. [4](#Fig4){ref-type="fig"}). When considering each group separately, there was a significant positive correlation in the PDD group (*ρ* = 0.66, *p*~FDR~ = 0.01), whereas there were no significant correlations in the other three groups (all *p* \> 0.1). Fig. 4Correlations between alpha reactivity and NBM volume. Spearman's correlations between alpha reactivity and normalised NBM volume across all groups and in each group separately. *p* values are FDR (false discovery rate)-corrected for multiple comparisons. AD, Alzheimer's disease; DLB, dementia with Lewy bodies; FDR, false discovery rate; HC, healthy controls; NBM, nucleus basalis of Meynert; PDD, Parkinson's disease dementia

Correlations between alpha reactivity and NBM volume were similar when using the standard alpha frequency band (Section 3 of the [Supplementary Material](#MOESM1){ref-type="media"}).

Correlations with clinical scores {#Sec14}
---------------------------------

In PDD, alpha reactivity was positively correlated with MMSE (*ρ* = 0.51, *p* = 0.035). However, this correlation did not survive correction for multiple comparisons. All other correlations between alpha reactivity and NBM volumes and clinical scores were not significant (all *p* \> 0.1).

Effect of dopaminergic medication in the LBD group {#Sec15}
--------------------------------------------------

There were no significant differences between LBD patients who were taking dopaminergic medication compared to those not taking these medications (Supplementary Table S[6](#MOESM1){ref-type="media"}). Furthermore, in those patients who were taking dopaminergic medication, there were no significant correlations between any EEG measures and LEDD (Supplementary Table S[6](#MOESM1){ref-type="media"}).

Discussion {#Sec16}
==========

In this study, we investigated EEG alpha reactivity in patients with LBD compared to AD and healthy controls and its relation to cholinergic system integrity as measured by NBM volume. We found a reduction in alpha reactivity in the dementia groups compared to controls which is in line with previous EEG studies in AD \[[@CR19], [@CR20]\] and MEG studies in DLB \[[@CR21]\] and PDD \[[@CR22]\]. Importantly, for the first time, we also showed that alpha reactivity is more severely affected in DLB and PDD compared to AD. Furthermore, in agreement with previous findings in healthy participants \[[@CR17], [@CR18]\], we found evidence for an involvement of the cholinergic system in modulating alpha reactivity, specifically in PDD patients.

Since alpha reactivity is determined by the difference between eyes-closed and eyes-open alpha power, a reduction in alpha reactivity as observed in the dementia groups can occur in two different ways (see Fig. [5](#Fig5){ref-type="fig"}). In AD, eyes-closed alpha power was reduced compared to controls while eyes-open alpha power was not significantly different from healthy control levels. In the LBD group, the opposite was the case: while eyes-closed alpha power was not significantly reduced compared to controls, eyes-open alpha power was significantly increased compared to controls and AD (after taking into account individual alpha peak frequencies). Furthermore, in AD, there was a strong positive correlation between alpha reactivity and individual alpha peak frequency, indicating that the reduction in alpha reactivity in this group might be more related to general alpha power reduction and alpha slowing \[[@CR26]\]. In contrast, in LBD, even though the general EEG slowing was slightly more severe than in AD, there was no significant correlation between alpha reactivity and alpha slowing, indicating that the loss of alpha reactivity might be a process that is more independent from general EEG slowing than in AD. Instead, loss of alpha reactivity in LBD might be more related to a lack of neuronal desynchronization upon opening the eyes. Fig. 5Interpretation of alpha reactivity changes. Illustration of how a reduction in alpha reactivity can be mainly due to a decrease in eyes-closed alpha power (in AD) or an increase in eyes-open alpha power (in LBD) compared to controls. AD, Alzheimer's disease; LBD, Lewy body dementia; HC, healthy controls

In the healthy human brain, opening of the eyes normally leads to a suppression of alpha power due to neuronal desynchronization \[[@CR15], [@CR16]\]. This state of low alpha power has been associated with highest levels of cortical responsiveness and has been suggested to be a more externally oriented brain state in which it is easiest for external stimuli to reach the cortex \[[@CR33]\]. In contrast, higher eyes-open alpha power indicates a more internally oriented state making it harder for external stimuli to be perceived \[[@CR33]\]. Evidence comes from studies of pre-stimulus alpha power which showed that performance is highest if pre-stimulus alpha power is low \[[@CR34]\]. However, the extent of alpha power suppression is not only important for processing of visual stimuli, but has also been related to attention and cognitive performance more generally. Low alpha power has been associated with higher activity in attention networks \[[@CR35]\]. Furthermore, the extent of alpha suppression upon eyes opening has been shown to be positively correlated with cognitive performance \[[@CR36]\] and has been related to attention and cognitive load \[[@CR37]\]. Simultaneous EEG-fMRI studies have reported a negative relationship between blood oxygen level dependent (BOLD) signal and alpha power indicating a simultaneous occurrence of occipital alpha power decrease and neuronal activation in the occipital cortex and other cortical areas \[[@CR38], [@CR39]\].

The increase in eyes-open alpha power in LBD might therefore indicate a specific impairment in neuronal desynchronization. Instead of activating neurons in primary and secondary visual areas when opening the eyes, the cortex of LBD patients seems to stay in a more synchronised state which might lead to a loss of cortical responsiveness. This in turn might lead to problems with attention and cognition \[[@CR36], [@CR37]\].

Several previous studies have investigated the mechanisms that lead to neuronal desynchronization when opening the eyes and thereby modulate alpha reactivity. There is compelling evidence for a role of the cholinergic system \[[@CR17], [@CR18]\]. The suppression of alpha power from eyes closed to eyes open has been shown to be related to an increase in functional connectivity between the NBM and primary visual areas \[[@CR17]\]. Furthermore, white matter integrity along fibre tracts connecting the NBM with occipital areas was negatively correlated with alpha reactivity. These findings suggest that cholinergic drive from the NBM might play an important role in modulating the reduction in alpha power from eyes closed to eyes open \[[@CR17]\]. Additionally, Osipova et al. \[[@CR18]\] showed that alpha power suppression upon opening the eyes was impaired when cholinergic neurotransmission was temporarily blocked by the cholinergic antagonist scopolamine, further suggesting that the integrity of the cholinergic system is crucial for alpha power suppression.

In the present study, across all groups and in the PDD group in particular, loss of alpha reactivity was related to volume loss within the NBM. The failure to activate neural sources in occipital cortex upon opening the eyes might therefore be due to a loss of cholinergic drive from the NBM which is in line with these previous studies \[[@CR17], [@CR18]\]. The lack of a specific association between alpha reactivity and NBM volume in DLB might be due to the fact that functional impairment within the cholinergic system can precede structural abnormalities; in particular, it has been shown that even prior to neurodegeneration, alpha-synuclein can reduce cholinergic neurotransmitter production \[[@CR9]\]. In contrast, PDD patients with a comparable level of cognitive impairment typically have a longer disease duration which might lead to structural abnormalities within the cholinergic system playing a greater role in the loss of alpha reactivity in these patients. Furthermore, PDD patients show less AD co-pathology than patients with DLB \[[@CR40]\], making PDD a "purer" alpha-synucleinopathy which might explain the discrepant findings in these two groups.

The observed association between alpha reactivity and the cholinergic system---if replicated in other studies---might suggest alpha reactivity as an interesting potential measure of treatment response in clinical trials which seek to remediate cholinergic function.

Contrary to our hypothesis, alpha reactivity was not significantly correlated with measures of cognitive fluctuation severity in LBD. This might be due to the fact that alpha reactivity was quite severely reduced in most patients and most of them had cognitive fluctuations, which might have led to a floor effect. The fact that AD patients, who have less severe cognitive fluctuations compared to LBD \[[@CR25]\], showed a less severe reduction in alpha reactivity might indicate that loss of alpha reactivity is related to the presence of cognitive fluctuations, while a relationship between alpha reactivity and cognitive fluctuation severity is more difficult to establish based on the present results.

We decided to use individual alpha peak frequencies to determine alpha power instead of using a fixed alpha frequency band (usually from 8 to 12 Hz) \[[@CR21], [@CR22]\]. This was done to account for a shift of the alpha peak to slower frequencies in AD and LBD \[[@CR26], [@CR27]\]. The mean alpha peak in the LBD group therefore lies within a frequency range that has been termed pre-alpha \[[@CR41], [@CR42]\], but is also considered to represent the fast-theta band in other studies \[[@CR27]\]. However, we showed that alpha reactivity differences between groups and the association with NBM volume remained the same when repeating the analysis using the standard alpha frequency band.

A potential limitation of the present study is the fact that most dementia patients were taking cholinesterase inhibitors which have been shown to influence the cortical EEG signal by increasing eyes-closed alpha power and reducing slow-wave activity \[[@CR43]--[@CR45]\]. Due to the low number of patients not taking these medications, it was not possible to study the effect of cholinesterase inhibitors on the present results nor would it be ethical to withdraw these medications. However, investigating the effect of cholinergic medication on alpha reactivity in AD and LBD will be an important step of future research which will also help to better understand the relationship between alpha reactivity and cholinergic neurotransmission and evaluate the potential use of alpha reactivity as a predictor of treatment response.

A further potential limitation is the use of dopaminergic medication in many LBD patients which has also been shown to influence EEG signals by increasing eyes-closed alpha power \[[@CR46], [@CR47]\]. However, we did not find differences between LBD patients who were taking dopaminergic medication compared to those patients not taking these medications, and there were no significant correlations between LEDD and the EEG measures included in the present study.

Conclusions {#Sec17}
===========

In conclusion, we showed that LBD patients show an impairment in neuronal desynchronization upon opening the eyes which distinguishes these patients from healthy controls and patients with AD and which might be related to a loss of cholinergic drive from the NBM in PDD. While the importance of a general slowing of the EEG signal in LBD has been discussed in many studies \[[@CR26], [@CR27]\], changes in eyes-open resting EEG in these patients have not been investigated in detail. The present study therefore complements previous research by showing that studying eyes-open EEG data can provide important new insights into changes in brain state in LBD.
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